world-biomarkers-pharma-biotech-2017-tracks

10 / 28

Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 34
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
RNAi-based tailored therapeutic strategies: Are we there yet?
Şükrü Tüzmen1,2
1Eastern Mediterranean University, Turkey
2Translational Genomics Research Institute, USA
Aclassical technique to determine the function of a gene is to experimentally inhibit its gene expression in order to examine
the resulting phenotype or effect on molecular endpoints and signaling pathways. RNA interference (RNAi) is one of the
recent discoveries of a naturally occurring mechanism of gene regulation facilitated by the induction of double stranded RNA
into a cell. This event can be utilized to silence the expression of specific genes by transfecting mammalian cells with synthetic
short interfering RNAs (siRNAs). siRNAs can be designed to silence the expression of specific genes bearing a particular target
sequence and may potentially be presented as a therapeutic strategy for inhibiting transcriptional regulation of genes, which in
such instances constitute a more attractive strategy than small molecule drugs. Low dose drug and siRNA combination studies
are promising strategies for the purpose of identifying synergistic targets that facilitate reduction of undesired gene expression
and/or cell growth depending on the research of interest. Commercially available RNAi libraries have made high-throughput
genome-scale screening a feasible methodology for studying complex mammalian cell systems. However, it is crucial that any
observed phenotypic change be confirmed at either the mRNA and/or protein level to determine the validity of the targeted
genes. Currently, qPCR is widely utilized for accurate evaluation and validation of gene expression profiling. In this study, we
describe a high-throughput screening of RNAi based gene knock-down approach and qPCR validation of specific transcript
levels. Considering such advantageous applications, siRNA technology has become an ideal research tool for studying gene
function in research fields including Pharmaceutical Biotechnology, and holds the promise that the utilization of siRNA-based
therapeutic agents will accelerate drug discovery in clinical trials.
Recent Publications:
1. Son A Y, Tüzmen Ş and Hizel C (2013) Omics for Personalized Medicine, “Designing and Implementing
Pharmacogenomics Study: Appropriateness and Validation of Pharmacogenomics” Chapter 6. Springer. 97-122.
2. Tuzmen S, Tuzmen P, Arora S, Mousses S., Azorsa D (2011) “RNAi-Based Functional Pharmacogenomics”, Methods
and Protocols, In: Methods in Molecular Biology, Disease Gene Identification, Part 4, Johanna K. DiStefano Ed.,
Springer, New York, USA. 700: 271-290.
3. Sevtap Savas, David O Azorsa, Hamdi Jarjanazi, Irada Ibrahim-Zada, Irma M. Gonzales, Shilpi Arora, Meredith C.
Henderson, Yun Hee Choi, Laurent Briollais, Hilmi Ozcelik, and Sukru Tuzmen (2011) “NCI60 cancer cell line panel
data and RNAi analysis help identify EAF as a modulator of simvastatin and lovastatin response in HCT-116 Cells,
PLoS ONE (SCIE). 6 (4): 18306.
4. Sukru Tuzmen, Jeff Kiefer, and Spyro Mousses (2007) Validation of siRNA knockdowns by quantitative real-time
PCR”, Methods in Molecular Biology, In: Methods in Molecular Biology, Protocols for Nucleic Acid Analysis by Non-
Radioactive Probes, Second Edition, E. Hilario and J. Mackay Eds., Humana Press, Totowa, USA. 535: 177-203.
Biography
Şükrü Tüzmen is a Molecular Biologist and Geneticist. He has more than 28 years of multi-disciplinary research experience integrating studies of the molecular
basis of human diseases, including cancer genetics. He has a passion for advancing the molecular genetics of diseases by studying the associations between
drugs, genes, pathways, and diseases. His mission is to discover and validate links between gene states and disease phenotypes, and further use these links to
identify druggable targets to be utilized as biomarkers in the early diagnostic stages of genetic diseases. He has focused his career on developing and applying
cutting edge methods and technologies to ensure excellence in translation of his basic scientific research including cancer genetics, from bench to bedside. He has
been invited to deliver talks in many national and international settings, and he has served on many expert panels including The Research Grant Council, Hong
Kong, China.
Şükrü Tüzmen, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109